Last reviewed · How we verify
NCT06602167
Electroacupuncture Combined With Self-administered Acupressure for the Prevention of Capecitabine-Associated Hand-Foot Syndrome
NA trial testing True electroacupuncture + True self-administered acupressure in Capecitabine in 220 participants. Currently enrolling.
30 July 2027
Quick facts
| Lead sponsor | Affiliated Hospital of Qinghai University |
|---|---|
| Phase | NA |
| Status | Recruiting now |
| Study type | INTERVENTIONAL |
| Allocation | randomized |
| Design | parallel |
| Masking | triple |
| Primary purpose | prevention |
| Enrollment | 220 |
| Start date | 8 October 2024 |
| Primary completion | 30 July 2027 |
| Estimated completion | 31 December 2027 |
| Sites | 1 location across China |
Drugs / interventions tested
- True electroacupuncture + True self-administered acupressure
- Doctor-prescribed treatment — full drug profile →
- Sham electroacupuncture + Sham self-administered acupressure
Conditions studied
- Capecitabine — all drugs for Capecitabine →
- Hand-foot Syndrome — all drugs for Hand-foot Syndrome →
- Electroacupuncture — all drugs for Electroacupuncture →
- Self-administered Acupressure — all drugs for Self-administered Acupressure →
Sponsor
Affiliated Hospital of Qinghai University
Who can join
Adults 18 to 85, any sex, with Capecitabine or Hand-foot Syndrome. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
This study hypothesizes that electroacupuncture combined with self-administered acupressure plus doctor-prescribed treatment is effective in preventing Hand-Foot Syndrome (HFS) caused by capecitabine. It aims to explore the effectiveness of this combined approach in preventing HFS in patients with malignant tumors undergoing oral capecitabine treatment. Further exploration of prevention and treatment methods may enhance the quality of life for patients during the treatment process.
Publications & conference data
No peer-reviewed publications indexed yet for this trial.
Verify or expand the search:
- PubMed search for NCT06602167
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other recruiting trials for Capecitabine
Currently open trials in the same condition.
- NCT06405490 — NALIRI-XELOX+AK104 for First-line Treatment of Advanced PDAC · Phase 2 · recruiting
- NCT05290194 — Radiotherapy Combined With PD-1 Monoclonal Antibody and Capecitabine in the Treatment of Nasopharyngeal Carcinoma · Phase 2 · recruiting
- NCT05022030 — First-line mCapOX+Cetuximab vs. mFOLFOX6+Cetuximab for Metastatic Left-sided CRC With Wild-type RAS/BRAF Genes · Phase 2 · recruiting
Other Affiliated Hospital of Qinghai University trials
Trials by the same sponsor.
- NCT07208305 — Olanzapine Plus Metoclopramide for the Prevention of Opioid-Induced Nausea and Vomiting · Phase 3 · recruiting
- NCT06772935 — Electroacupuncture Treatment of Peripheral Neuropathy After Taxane Chemotherapy for Breast Cancer · NA · recruiting
- NCT05094310 — Genetic Predictors of Response to Acupuncture for Cancer-related Fatigue Among Breast Cancer Patients After Chemotherapy · NA · unknown
- NCT05275569 — Personalized Electroacupuncture Treatment for Chemotherapy-induced Nausea and Vomiting in Breast Cancer (PET) · NA · unknown
- NCT05099562 — Precision Acupuncture in the Treatment of Peripheral Neuropathy After Taxanes Chemotherapy in Breast Cancer · NA · unknown
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT06602167 (US National Library of Medicine, public domain)
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by Affiliated Hospital of Qinghai University
- Last refreshed: 12 December 2024
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT06602167.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing